Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi

Protalix BioTherapeutics projects total revenue for FY26 to be between $78 million and $83 million, which includes a $25 million milestone payment from Chiesi. The company anticipates that revenue from Elfabrio sales will be approximately $33 million to $35 million, while Elelyso sales are expected to generate about $20 million to $23 million. Protalix maintains a strong balance sheet with no debt, focusing on advancing its clinical programs and commercial partnerships.